S 1040 — Drug Competition Enhancement Act
Congress 119 · introduced 2025-03-13
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Sponsors
No sponsorships on file.
Lobbied by (15)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
Action timeline
- — Read twice and referred to the Committee on the Judiciary.
- · 10000 — Introduced in Senate
- — Committee on the Judiciary. Ordered to be reported with an amendment favorably.
- — Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
- — Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
- · 14000 — Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
Text versions
Connected on the graph
Inbound (13)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | CAMBIA HEALTH SOLUTIONS | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | SANOFI U.S. SERVICES, INC. | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | CONSERVATIVES FOR PROPERTY RIGHTS | lobbies_on_bill | — | S. 1040 | lobbying_bill_mention |
| 2026-01-01 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | ASSOCIATION FOR ACCESSIBLE MEDICINES | lobbies_on_bill | — | S. 1040 | lobbying_bill_mention |
| 2026-01-01 | BLUECROSS BLUESHIELD OF TENNESSEE, INC. | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | lobbies_on_bill | — | S. 1040 | lobbying_bill_mention |
| 2026-01-01 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | AMGEN USA INC. | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | GENENTECH, INC. | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | COUNCIL FOR INNOVATION PROMOTION (C4IP) | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
| 2026-01-01 | PFIZER, INC. | lobbies_on_bill | — | S.1040 | lobbying_bill_mention |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2 | $90,000 | 0 | $0 | $90,000 |
| 2 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 1 | $90,000 | 0 | $0 | $90,000 |
| 3 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2 | $70,000 | 0 | $0 | $70,000 |
| 4 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 1 | $60,000 | 0 | $0 | $60,000 |
| 5 | PFIZER, INC. | 1 | $60,000 | 0 | $0 | $60,000 |
| 6 | GENENTECH, INC. | 1 | $60,000 | 0 | $0 | $60,000 |
| 7 | AMGEN USA INC. | 1 | $60,000 | 0 | $0 | $60,000 |
| 8 | SANOFI U.S. SERVICES, INC. | 1 | $60,000 | 0 | $0 | $60,000 |
| 9 | COUNCIL FOR INNOVATION PROMOTION (C4IP) | 1 | $50,000 | 0 | $0 | $50,000 |
| 10 | CONSERVATIVES FOR PROPERTY RIGHTS | 1 | $25,000 | 0 | $0 | $25,000 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
0 predicted yes (0%) · 543 predicted no (100%) · 0 unknown (0%)
By party: · R: 0 yes / 277 no · D: 0 yes / 263 no · I: 0 yes / 3 no
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-01-01 · lobbied on by CAMBIA HEALTH SOLUTIONS (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by CONSERVATIVES FOR PROPERTY RIGHTS (s. 1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by SANOFI U.S. SERVICES, INC. (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (s. 1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by GENENTECH, INC. (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by COUNCIL FOR INNOVATION PROMOTION (C4IP) (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by BLUECROSS BLUESHIELD OF TENNESSEE, INC. (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by THE CAMPAIGN FOR SUSTAINABLE RX PRICING (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ASSOCIATION FOR ACCESSIBLE MEDICINES (s. 1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by AMGEN USA INC. (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by PFIZER, INC. (s.1040) · lobbying_bill_mention
- 2026-01-01 · lobbied on by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (s.1040) · lobbying_bill_mention